



3115 Merryfield Row, Suite 120,
San Diego, CA 92121

0 858-684-1300

Update on the Phase 3 PROSERA study of investigational therapy seralutinib in pulmonary arterial hypertension (PAH)

Topline results from the Phase 3 PROSERA study have now been released. The study narrowly missed its primary endpoint of improvement in 6-minute walk distance (6MWD) at week 24. This outcome appears to have been influenced in part by an unexpectedly large improvement in walk distance in the placebo group, particularly in certain geographic regions, which reduced the measurable difference between the treatment and placebo arms.

It is worth noting that the results showed encouraging findings in the key secondary endpoints which favored seralutinib, including clear significant reductions in NT-proBNP, improvements in clinical status, and reductions in risk scores, all of which are important indicators of disease severity and progression. Change in walk distance also continued to improve out to ~1 year on study, suggesting potential for increased treatment effect of seralutinib over time compared with placebo.

The study also showed meaningful treatment effects in patients with intermediate and high-risk disease. These findings reinforce what was previously observed in the Phase 2 TORREY study and suggest that seralutinib may have particular benefit in patients with more advanced disease.

Patients with connective tissue disease-associated PAH also saw a significant improvement in walking distance – indicating seralutinib’s potential in this difficult-to-treat subgroup.

Importantly, the open-label extension study will continue, allowing patients to remain on treatment while further data are collected.

Gossamer Bio has announced plans to continue analyzing the data and to engage with regulatory authorities to determine next steps.

We will continue to monitor developments closely and share updates as more information becomes available. We look forward to hearing about the results.

Read more on the company press release [at this link](#).